Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review

Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang

Comparison between fenofibrate and pemafibrate

CVD, cardiovascular disease
DM, diabetes mellitus
PPAR, peroxisome proliferator-activated receptor
RCT, randomized clinical trial

Highlights

- This review summarizes the efficacy and safety data of fenofibrate in Asian subjects.
- The cardiovascular benefit of fenofibrate has been proven in certain populations.
- On the contrary, pemafibrate didn't show cardiovascular benefit in patients with diabetes.
- Both fibrates have distinct characteristics in reduction in LDL-C and apo-B levels.

dmj

DIABETES & METABOLISM JOURNAL

Check for updates

Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review

Chaicharn Deerochanawong[1], Sin Gon Kim[2], Yu-Cheng Chang[3]

[1]Diabetes and Endocrinology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand,
[2]Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea,
[3]Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan

Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, and is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different Asian regions are limited. This narrative review summarizes the efficacy and safety data of fenofibrate in Asian subjects with dyslipidemia and related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, and diabetic nephropathy). Long-term fenofibrate use resulted in fewer cardiovascular (CV) events and reduced the composite of heart failure hospitalizations or CV mortality in type 2 diabetes mellitus. Fenofibrate plays a significant role in improving irisin resistance and microalbuminuria, inhibiting inflammatory responses, and reducing retinopathy incidence. Fenofibrate plus statin combination significantly reduced composite CV events risk in patients with metabolic syndrome and demonstrated decreased triglyceride and increased HDL-C levels with an acceptable safety profile in those with high CV or ASCVD risk. Nevertheless, care is necessary with fenofibrate use due to possible hepatic and renal toxicities in vulnerable individuals. Long-term trials and real-world studies are needed to confirm the clinical benefits of fenofibrate in the heterogeneous Asian population with dyslipidemia.

Keywords: Asian people; Diabetes mellitus; Dyslipidemia; Fenofibrate; Fibric acids; Hypertriglyceridemia

INTRODUCTION

Epidemiology of dyslipidemia in the Asian region

Dyslipidemia refers to plasma lipid abnormalities including elevated levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) or triglycerides (TG), and reduced levels of high-density lipoprotein cholesterol (HDL-C), or a combination of these attributes [1]. Hypertriglyceridemia is among the most common dyslipidemias observed in clinical practice and is characterized by increased plasma TG levels (fasting state, >150 mg/dL; fed state, >175 mg/dL) [2,3]. Primary causes of hypertriglyc-

eridemia include congenital disorders while secondary causes include metabolic syndrome, type 2 diabetes mellitus (T2DM), central obesity, hypothyroidism, chronic kidney disease (CKD), and drug-induced dyslipidemia [4].

Elevated TG either independently or together with low levels of HDL-C and high levels of small, dense LDL poses a high cardiovascular (CV) risk as part of atherogenic dyslipidemia [5]. The Asia Pacific Cohort Studies Collaboration, reported serum TG as an independent predictor of CV risk. After adjustment for major CV risk factors, participants with TG levels in the highest fifth (≥168.3 mg/dL) had a 70% higher risk of

Corresponding author: Sin Gon Kim https://orcid.org/0000-0002-7430-3675
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 02841, Korea
E-mail: k50367@korea.ac.kr

coronary heart disease (CHD) death, whereas for fatal or non-fatal stroke and fatal or nonfatal CHD, an increased risk of 50% and 80%, respectively, was noted versus those in the lowest fifth (≤62.0 mg/dL) [6].

The prevalence of dyslipidemia differs substantially between the Asia-Pacific countries. Among the East and Southeast Asian countries, it ranged from 9.0% (Indonesia) to 46.9% (Philippines) for high TC, 7.8% (Taiwan) to 47.2% (Philippines) for high LDL-C, 10.1% (Taiwan) to 71.3% (Philippines) for low HDL-C, and 15.1% (China) to 38.6% (Philippines) for high TG [7]. The Responding to Increasing Cardiovascular Disease Prevalence (REDISCOVER) study of Malaysian adults reported the prevalence of raised TC (64.0%), LDL-C (56.7%), TG (37.4%), non-HDL-C (56.2%), and low HDL-C (36.2%) [8]. As per the 'dyslipidemia fact sheets in Korea 2020,' the prevalence of dyslipidemia in 2018 was 38.4% and increased TC, LDL-C, TG, and low HDL-C was 20.7% (crude), 19.2%, 16.1%, and

17.7%, respectively [9]. These disparities are mainly because of differences in types of the definition used for dyslipidemia in each country, lipid assays used, prescription rates of lipid-lowering drugs, year of investigation, age distribution of patients, ethnic differences, regional variations, and socioeconomic status [7]. Furthermore, a residual risk for atherosclerotic cardiovascular disease (ASCVD) persists when raised TG and lowered HDL-C levels are uncontrolled with statins [10]. Therefore, to improve the awareness and treatment rates and to reduce the prevalence of dyslipidemia and associated CV risk, country-specific epidemiological surveys and management guidelines in accordance with the national settings are recommended.

Fenofibrate: a peroxisome proliferator-activated receptor α agonist

Fibric acid derivatives or fibrates decrease TG or TG-rich lipo-

Fig. 1. Mechanism of action of fenofibrate. Fenofibrate mediates its lipid-lowering effects by activating the peroxisome proliferator-activated receptor-α (PPAR-α), which then forms a heterodimer with the nuclear receptor retinoid X receptor (RXR); and interacts with the peroxisome proliferator response element (PPRE) of target genes, including lipoprotein, fatty acid (FA), and cholesterol metabolism regulation genes. Fenofibrate enhances plasma clearance of atherogenic triglyceride (TG)-rich lipoproteins and lipolysis via activation of lipoprotein lipase and ApoAV, and reduced synthesis of the lipoprotein lipase inhibitor ApoCIII. It stimulates the production of high-density lipoprotein (HDL), ApoAI, and ApoAII, and reduces synthesis of very low-density lipoprotein (VLDL) and ApoB, while increasing the expression of adenosine triphosphate-binding cassette transporter A1 (ABCA1) and scavenger receptor B1 (SR-B1), leading to HDL-mediated cholesterol efflux from macrophages. Additionally, fenofibrate promotes β-oxidation, reduces the availability of free FAs, and thus inhibits TG synthesis; and inhibits the *de novo* FA synthesis by reducing the activities of acetyl-coenzyme A (CoA) carboxylase and FA synthase. Symbol ↑ indicates increase; ↓ indicates decrease; ⊝ indicates inhibition.

proteins and raise HDL levels through various peroxisome proliferator-activated receptor α (PPAR-α) actions [11,12]. Fenofibrate, the most commonly used PPAR-α agonist, exerts its lipid-lowering effects by activating the PPAR-α. Fig. 1 shows the mechanism of action of fenofibrate [13,14]. Additionally, fenofibrate maintains peroxisomal biogenesis and function, through PPAR-α pathway activation. It also attenuates liver injury and enhances hepatic fatty acid (FA) oxidation. The improved peroxisomal fitness induced by fenofibrate mediates protective effects against non-alcoholic fatty liver disease (NAFLD) as well [15].

Fibrates including fenofibrate, bezafibrate, gemfibrozil, ciprofibrate, and fenofibric acid [16-18] are recommended for the treatment of patients with dyslipidemia in Asia. Although treatment guidelines are available for each specific region, data on fenofibrate use across different ethnic regions of Asia are limited. It has been challenging to propose consensus management recommendations for dyslipidemia for these heterogeneous populations. In this review, we summarized the efficacy and safety data of fenofibrate in patients with dyslipidemia or hypertriglyceridemia and comorbid conditions, which may aid healthcare practitioners in informed clinical decision-making. The literature published in the English language in Embase and PubMed from 2012 to 2022 was reviewed. The keywords including fenofibrate, dyslipidemia, hypertriglyceridemia, T2DM, CV effect, and Asia were used as search strategy in different combinations to review the relevant publications.

POTENTIAL ROLE OF FENOFIBRATE

Dyslipidemia or hypertriglyceridemia with or without high risk of cardiovascular disease

Fenofibrate has demonstrated clinical benefits in patients with mixed or combined hyperlipidemia or hypertriglyceridemia with or without high CV risk (Supplementary Table 1). Fenofibrate significantly improved the coronary flow velocity reserve and arterial stiffness in Chinese patients with hypertriglyceridemia, demonstrating a potential protective role against atherosclerosis by normalizing endothelial disorders [19].

High risk of cardiovascular disease or ASCVD

Fenofibrate shows anti-inflammatory effects in selected high-risk patients with hypertriglyceridemia. Fenofibrate therapy decreased C-reactive protein (CRP) levels more in patients with high baseline CRP (≥1 mg/L) and without severe overweight

(body mass index, ≤26 kg/m^2; P=0.097) and/or in patients with low baseline HDL-C (<40 mg/dL) [20].

Statins plus fibrate combination could be beneficial in patients with high CV risk. However, the safety of this combination should be considered, and monitoring of aminotransferase levels is recommended to avoid hepatic complications [21, 22]. Fenofibrate addition to statins improved lipid levels with an acceptable safety profile in Asian patients with mixed hyperlipidemia and high CV risk. The first randomized controlled trial (RCT) compared the non-lipid effects of rosuvastatin plus fenofibrate versus rosuvastatin monotherapy in this population. Combination therapy resulted in a significantly greater reduction in TG levels (after treatment, 143±81 mg/dL vs. 180±87 mg/dL, P=0.01) and a higher increase in HDL-C levels (after treatment, 53.7±12.8 mg/dL vs. 49.1±9.6 mg/dL. P=0.02) than the monotherapy [23]. In a phase 4 study of Chinese patients with dyslipidemia and high CV risk, fenofibrate addition to the existing statin treatment significantly decreased TG (by 38.1%) and increased HDL-C levels (by 17.4%) after 8 weeks of combination therapy (P<0.01 for both) [24]. A phase 4 RCT in Korean patients with elevated TG levels despite statin monotherapy, also reported significant improvements in the TG and HDL-C levels (P<0.05 for both) after 8 weeks of treatment with choline fenofibrate plus statin versus statin monotherapy [25]. Pitavastatin plus fenofibrate was associated with a greater reduction in non-HDL-C (between-group difference, −12.45%; P<0.001), and significant improvement in other lipid levels, apolipoproteins (Apos), and inflammatory markers (fibrinogen and high-sensitivity C-reactive protein [hsCRP]) with a safety profile similar to that of statin monotherapy in high-risk Korean patients with mixed dyslipidemia [10].

Furthermore, a study in Korean patients with ≥1 CV risk factors, at low LDL-C goal but with high TG levels, receiving fenofibrate for the first time showed a median change in TG and HDL-C of −60.0% and 14.3%, respectively (P<0.001 for both). The study indicated that in real-world practice, only half of the patients receiving fenofibrate achieved optimal TG levels (<150 mg/dL), and more attention is required while treating males or patients with diabetes [26].

Dyslipidemia without high cardiovascular disease or ASCVD risk

In Korean patients with hypertriglyceridemia, omega-3 FA and fenofibrate showed similar improvements in TG levels and endothelium-dependent dilation. However, fenofibrate had con-

Table 1. Characteristics and outcomes of studies using mono- or combination therapy of fenofibrate in patients with comorbid diseases

Study	Study design	Patient population	Study drug (no. of patients)	Comparator or control (no. of patients)	Treatment duration (and/or safety follow-up)	Outcomes with fenofibrate alone/ in combination
Yan et al. (2014) [37]	Interventional study	T2DM and hypertriglyceridemia	Micronized fenofibrate (160 mg/day) (n=33)	Acipimox (500 mg/day) (n=33)	2 months	Both treatments increased HDL2b and decreased HDL3a, small, dense LDL, and oxidized LDL; No significant difference in Lp(a) levels after fenofibrate therapy; No clinically significant side effects in the two treatment groups
Shinnakasu et al. (2017) [38]	Interventional study	T2DM	Fenofibrate (160 mg/day) plus ezetimibe (10 mg/day) (n=25)	Statin (n=25)	12 weeks	Decreased TG and small LDL-C and increased small fraction of HDL-C; Significantly improved FMD
Jo et al. (2021) [41]	Real-world, population-based cohort study	T2DM	Fenofibrate (n=5,057)	Nonusers of fenofibrate and /or omega-3 FA (n=5,057)	Follow-up, 3 years	Significantly lowered composite outcome of the first occurrence of MI, stroke, PCI, and CV death
Sun et al. (2020) [60]	Randomized (no placebo) controlled study	T2DM with microalbuminuria and hypertriglyceridemia	Fenofibrate (200 mg/day), while the previous type and dose of statin therapy were continued (n=28)	Control group (n=28)	180 days	Reduced progression to microalbuminuria without increases in eGFR impairment
Kim et al. (2019) [62]	Propensity-matched cohort study	Metabolic syndrome	Fenofibrate plus statin (n=2,156)	Statin (n=8,549)	Follow-up, 6 years	Significantly reduced risk of major CV events; No difference in change in mean serum creatinine level over time
Shi et al. (2018) [54]	Retrospective, matched case-control study	T2DM with either no DR or NPDR	Fenofibrate (n=48)	Nonusers of fenofibrate (n=41)	Regular or intermittent use of fenofibrate for at least 1 year	Significantly thicker RNFL in the superior quadrant of the right eye in patients with early DR
Lin et al. (2020) [55]	Population-based, retrospective cohort study	T2DM without preexisting retinopathy or laser treatment	Fenofibrate (n=2,500)	Nonusers of fenofibrate (n=29,753)	3 months to >2 years	Reduced risk of incident retinopathy in a dose-dependent manner and decreased need for laser treatment
Kim et al. (2023) [57]	Propensity-matched cohort study	T2DM and metabolic syndrome	Statin plus fenofibrate (n=22,395)	Statin (n=43,191)	Median follow-up, 44 months	Significantly reduced risk of DR progression; Significantly lower risks of vitreous hemorrhage, laser photocoagulation and intravitreous injection therapy

T2DM, type 2 diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); TG, triglyceride; FMD, flow-mediated dilation; FA, fatty acid; MI, myocardial infarction; PCI, percutaneous coronary intervention; CV, cardiovascular; eGFR, estimated glomerular filtration rate; DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; RNFL, retinal nerve fiber layer.

siderably better effects on lipoprotein and metabolic profiles [27]. Omega-3 FA plus fenofibrate significantly decreased TG and TG/HDL-C ratio compared with fenofibrate alone or placebo ($P<0.001$). Although significant compared with placebo, the decrease in ApoB, non-HDL-C, hsCRP, fibrinogen, insulin, and glucose, and an improvement in flow-mediated dilation and insulin sensitivity were comparable between the combination and fenofibrate alone groups [28]. In the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) study of Japanese patients with combined hyperlipidemia, long-term therapy of fenofibrate plus ezetimibe significantly decreased LDL-C ($P<0.01$ for each) compared with fenofibrate or ezetimibe monotherapy and improved TG ($P<0.001$ for each) versus ezetimibe alone in [29]. Policosanol plus fenofibrate significantly improved the lipid parameters, arterial stiffness, and quality of life, with good tolerability in elderly patients with mixed dyslipidemia [30].

In addition, severe hypertriglyceridemia (TG levels >1,000 mg/dL) may induce acute pancreatitis [31]. Fenofibrate plus octreotide acetate demonstrated a significantly better ($P=0.037$) and synergistic therapeutic effect in Chinese patients with acute hyperlipidemia pancreatitis. The combination provided a more significant anti-inflammatory effect and protected liver function leading to the improved prognosis of these patients; and has been recommended for patients with acute pancreatitis having diabetes and fatty liver simultaneously [32].

Beneficial effects of fenofibrate have also been demonstrated in patients with comorbidities like T2DM, diabetic retinopathy (DR), diabetic nephropathy (DN), and metabolic syndrome (Table 1).

Type 2 diabetes mellitus
Hypertriglyceridemia is associated with insulin resistance and β-cell dysfunction that contribute to the incidence of T2DM [33,34]. Therefore, controlling hypertriglyceridemia and improving these two pathologic disturbances may prevent T2DM development. A retrospective cohort study showed that Taiwanese patients with dyslipidemia receiving fenofibrate ($n=2,806$) or gemfibrozil ($n=1,009$) were not associated with an increased risk of developing new-onset diabetes mellitus (NODM) and had a neutral risk for NODM [35]. Fenofibrate significantly decreased the homeostasis model assessment index 2 for β-cell function (HOMA2-%β) and insulin resistance (HOMA2-IR) and increased homeostasis model assessment index 2 for insulin sensitivity and McAuley index in impaired glucose tolerance pa-

tients with hypertriglyceridemia ($P=0.018$ for HOMA2-%β; $P<0.001$ for all other parameters) [36]. Similar benefits of significantly alleviated IR and decreased secreting load of β-cells with fenofibrate were observed in an interventional study conducted in Chinese patients with normal glucose tolerance [33].

An RCT conducted in Chinese patients with T2DM and hypertriglyceridemia showed that fenofibrate and acipimox were comparably efficacious in modifying the profile of atherogenic lipids and resulted in the metabolism of HDL subclasses maturation in these patients. TG and TC levels were significantly reduced, and HDL-C levels and ApoA-I/B-100 ratio were increased. Compared with the baseline, a significant increase in large-sized HDL2b, whereas a significant decrease in small-sized HDL3a, small, dense-LDL, and oxidized-LDL was noted in both treatment groups. However, the acipimox intensively decreased lipoprotein(a) levels [37]. In Japanese patients with T2DM, fenofibrate plus ezetimibe was effective in controlling the TG and LDL-C levels, by increasing the levels of HDL-C small fraction and decreasing the small LDL-C levels. Improvement of vascular function in these patients was significantly associated with an increase in the very-small fraction of HDL-C [38].

The two non-Asian RCTs, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD; conducted in Australia, New Zealand, and Finland) [39] and Action to Control Cardiovascular Risk in Diabetes-Lipid (ACCORD-Lipid; conducted in the United States and Canada) trials [40] did not show the benefit of cardiovascular disease (CVD) prevention with fenofibrate in patients with T2DM. However, a real-world, population-based cohort study ($n=63,727$) using the South Korean National Health Insurance Service data demonstrated that the long-term usage of fenofibrate reduced the rate of total and cardiac mortality, and CV events in patients with T2DM compared with non-users of fenofibrate and/or omega-3 FA. The primary endpoint (a composite of myocardial infarction, stroke, percutaneous coronary revascularization, and cardiac death) was significantly reduced in fenofibrate users versus those using neither fenofibrate nor omega-3 FA (13.4 vs. 15.5 per 1,000 person-years; hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.62 to 0.94; $P=0.010$). In subgroup analysis, the beneficial effect of fenofibrate was maintained consistently across all subsets of patients, including those grouped by LDL-C, TG, and HDL-C levels [41]. A recent analysis ($n=5,518$; follow-up, 4.7 years) of the ACCORD-Lipid trial demonstrated that in patients with T2DM receiving simvastatin, fenofibrate reduced the composite outcome of heart failure (HF) hospitalizations or CV death com-

pared with placebo ($P=0.048$). This beneficial effect was observed predominantly in patients receiving standard background glucose-lowering therapy (HR, 0.64; 95% CI, 0.48 to 0.85; $P_{interaction}=0.017$). A similar pattern was noted for HF hospitalizations alone [42].

Furthermore, the myocyte hormone irisin is linked to insulin resistance and metabolic disorders and might have implications for reducing CV risk [43,44]. Regulated on activation, normal T-cell expressed and secreted (RANTES), a CC chemokine is suggested to play an important role in inflammatory processes, and increased RANTES levels may be associated with a high CV risk [45]. Cross-sectional studies conducted in China have investigated the influence of fenofibrate therapy on serum irisin and RANTES levels in patients with T2DM with hypertriglyceridemia [43,45]. Treatment with fenofibrate for 8 weeks significantly decreased the serum irisin ($P=0.011$) and serum RANTES levels ($P=0.018$) from baseline, suggesting that fenofibrate plays a significant role in protecting against metabolic disorders by improving irisin resistance and by inhibition of inflammatory responses and CVD [43,45].

Results of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) trial, a multinational (countries, 24; not limited to the Asian population), randomized, placebo-controlled trial that evaluated CV outcomes with pemafibrate treatment have been recently published. In patients with T2DM, mild-to-moderate hypertriglyceridemia, and HDL-C ≤40 mg/dL, pemafibrate treatment failed to prove CV benefit compared with placebo. Pemafibrate reduced the levels of TG (−26.2%), very LDL-C (−25.8%), remnant cholesterol (−25.6%), and ApoCIII (−27.6%), but increased LDL-C (12.3%) and ApoB (4.8%) levels, compared with placebo. The incidence of major adverse CV events (primary composite endpoint) per 100 person-years was not lower in the pemafibrate group than in the placebo group ($P=0.67$). Also, the number of patients with venous thromboembolism (HR, 2.05; 95% CI, 1.35 to 3.17; $P<0.001$), pulmonary embolism (HR, 2.13; 95% CI, 1.20 to 3.89; $P=0.008$), or deep-vein thrombosis (DVT) (HR, 2.39; 95% CI, 1.37 to 4.33; $P=0.001$) was higher in the pemafibrate group than in the placebo group. However, the trial reported a lower incidence of NAFLD with pemafibrate treatment [46]. In contrast, fenofibrate reduced LDL-C (women, −9.8%; men, −3.3%) and ApoB (women, −10.4%; men, −5.8%) compared with placebo [47] and demonstrated no difference in the proportion of patients with DVT (fenofibrate vs. placebo, 1% vs. 1%) or pulmonary embolism (fenofibrate vs. placebo, 1% vs.

0.7%) in the FIELD trial [39].

Diabetic retinopathy

Besides the established lipid-lowering potential, fenofibrate is effective in preventing DR. The FIELD study [48] and the AC-CORD Eye study [49] demonstrated the benefits of fenofibrate in reducing the progression of DR, including DR requiring a laser treatment [48].

In an observational study of Chinese patients with T2DM, fenofibrate significantly reduced the inflammatory cytokine (including vascular endothelial growth factor, tumor necrosis factor-α, interleukin-1β, and lipoprotein-associated phospholipase A2) levels in the non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) groups. This indicated that DR may be ameliorated by the improved inflammatory response [50]. A retrospective observational analysis using the Japan Medical Data Center health claims database showed that of the 69,070 individuals with T2DM at baseline (cohort 1; with neither DR nor diabetic macular edema [DME]), about 5,687 individuals developed DR during the 3-year follow-up period. The proportion of bezafibrate and fenofibrate use was 54.4% and 45.5%, respectively. In patients without DR at baseline, fibrates use reduced the risk of newly developed DR (odds ratio [OR], 0.780; 95% CI, 0.663 to 0.918; $P=0.003$), whereas in patients with DR at baseline (cohort 2; with or without DME and no prior history of DR-related treatment), fibrates reduced the risk of incidence of DME (OR, 0.286; 95% CI, 0.122 to 0.670; $P=0.004$) and any treatments for DR (OR, 0.407; 95% CI, 0.193 to 0.857; $P=0.018$), including laser photocoagulation and vitrectomy [51]. In the Japan Diabetes Complication and its Prevention prospective study baseline survey, about 27.6% of patients with T2DM had NPDR and reported that the use of lipid-lowering medications (statin or fibrate) was associated with decreased odds of having NPDR in these patients. This protective association was also confirmed by propensity score (PS) adjustment for receiving fibrate and/or statin (OR, 0.80; 95% CI, 0.70 to 0.92; $P=0.002$) [52]. In a population-based study conducted in Taiwanese patients with T2DM and dyslipidemia, statin use reduced the risk of DR and the need for invasive treatments for vision-threatening diabetic retinopathy (VTDR) [53]. However, the cross-sectional analysis conducted by Kawasaki et al. [52] does not completely support the efficacy of statin plus fibrate in a longitudinal study, and these findings need to be confirmed with an ongoing longitudinal follow-up study.

In Chinese patients with T2DM with either no DR or NPDR

(at an early stage of DR), the retinal nerve fiber layer (RNFL) of the superior quadrant of the right eye was significantly reduced in the non-fibrate users compared with the fenofibrate users (t=2.384, P=0.019). A positive association was noted between fenofibrate use and the RNFL thickness of the right eye (P=0.042) [54]. In Taiwanese patients with T2DM (without pre-existing retinopathy or laser treatment before recruitment), long-term and regular use of fenofibrate decreased the risk of incident retinopathy in a dose-dependent manner and the need for laser treatments (fenofibrate users vs. nonusers, 4.88% vs. 6.46%) [55]. A recent multicenter cohort study reported fenofibrate use to be associated with a decreased risk of PDR (HR, 0.76; 95% CI, 0.64 to 0.90; P=0.001) and VTDR (HR, 0.92; 95% CI, 0.87 to 0.98; P=0.01) but not DME alone (HR, 0.96; 95% CI, 0.90 to 1.03; P=0.27) [56].

Furthermore, the Effectiveness of Fenofibrate Therapy in Residual Cardiovascular Risk Reduction in the Real-World Setting (ECLIPSE-REAL) EYE study (conducted as part of the ECLIPSE-REAL study) aimed to determine if fenofibrate therapy is beneficial for preventing the progression of DR in patients with T2DM and metabolic syndrome (age, ≥30 years) receiving statin therapy and at risk of CVD in a real-world setting. Patients were matched 1:2 by PS into the statin plus fenofibrate group (n=22,395) and the statin-only group (n=43,191). The primary outcome was a composite of DR progression including vitreous hemorrhage, vitrectomy, laser photocoagulation, intravitreal injection therapy, and retinal detachment. In this propensity-matched cohort study, fenofibrate plus statin therapy reduced the risk of DR progression than statin therapy alone. The incident rate of treatment-mediated progression of DR per 1,000 person-years was lower in statin plus fenofibrate group (8.68) versus the statin-only group (9.66) (HR, 0.88; 95% CI, 0.81 to 0.96; P=0.005). Fenofibrate was associated with a 14% lower risk of vitreous hemorrhage, lower rates of undergoing laser photocoagulation (14%), and intravitreous injection therapy (27%). The magnitude of preventing the progression of DR was higher in patients with DR at baseline as in FIELD and ACCORD Eye studies. When combined with statin, fenofibrate is associated with a lower risk of DR progression in patients with T2DM having metabolic syndrome [57].

Diabetic nephropathy

Approximately 20% to 40% of patients with T2DM with microalbuminuria progress to evident nephropathy, and about 20% with evident nephropathy develop end-stage renal disease [58].

The FIELD study showed that fenofibrate could reduce albuminuria and prevent DN progression. In the sub-study, serum creatinine and estimated glomerular filtration rate (eGFR) measurements suggested a less significant loss of renal function in the fenofibrate group versus placebo for 5 years [59]. The ACCORD study demonstrated a reduction of microalbuminuria and macroalbuminuria in the fenofibrate group [40]. Similarly, in another RCT involving Chinese patients with T2DM and hypertriglyceridemia, fenofibrate improved microalbuminuria and did not increase the eGFR impairment. After 180 days of fenofibrate treatment, uric acid and TG levels, urinary microalbumin/creatinine ratio (UACR), and HOMA-IR were significantly reduced, whereas HDL-C levels significantly increased compared with the baseline (P<0.05 for all metabolic parameters). Also, the decrease in uric acid, TG, and UACR was greater at 180 days in the fenofibrate group than in the control group (P<0.05 for all). A decrease in UACR was positively associated with the decreases in TG (P=0.042) and uric acid (P=0.024) in the fenofibrate group [60]. Likewise, the recent ACCORD-Lipid trial analysis showed that the fenofibrate therapy caused more transitory worsening of eGFR events but slowed long-term eGFR decrease [42].

A retrospective Taiwanese national cohort study compared the outcomes of all-cause mortality, CV death, and incidence of permanent dialysis and major adverse cardiac cerebrovascular events (MACCEs) among patients with advanced CKD treated with fenofibrate, statins, a combination of both, and none of these. The prevalence of T2DM was >70% in all the treatment groups after the inverse probability of treatment weighting. Both fenofibrate and statin groups showed a lower risk of CV death than the nonuser group (fenofibrate vs. nonuser: HR, 0.84; 95% CI, 0.75 to 0.94 and statins vs. nonuser: HR, 0.94; 95% CI, 0.90 to 0.97). The fenofibrate group had the lowest incidence of permanent dialysis and fenofibrate plus high-intensity statins demonstrated a lower risk of MACCEs. This study suggested that continuing fenofibrate in patients with advanced CKD resulted in a protective effect on CV outcomes comparable with statins, and also delayed the requirement for permanent dialysis [61].

Metabolic syndrome

Individuals of Asian origin are metabolically more susceptible to metabolic syndrome than those from another origin [62]. In the FIELD and ACCORD-Lipid trials, there was no decrease in major CV events in patients with diabetes. However, a statistically significant decrease in CV risk was noted in a subgroup of pa-

tients with atherogenic dyslipidemia [59,63,64]. Hence, studies investigating fenofibrate efficacy in CV risk reduction in this patient population are necessary. A 1:5 PS-weighted cohort study (ECLIPSE-REAL; fenofibrate plus statin treatment, $n=2,156$; statin monotherapy, $n=8,549$) evaluated the efficacy of fenofibrate as an add-on to statin treatment in reducing the risk of major CV events in Korean adults (≥ 40 years) with metabolic syndrome. Patients from the National Health Insurance Service-Health Screening Cohort database who had used statins for at least 3 months were included (pre-existing CVD, 9.2%; T2DM, 37.8%). The risk of composite CV events was significantly reduced with the combination treatment compared with statin monotherapy during 6 years of follow-up (adjusted HR, 0.74; 95% CI, 0.58 to 0.93; $P=0.01$). Significance was retained in the on-treatment analysis as well (HR, 0.63; 95% CI, 0.44 to 0.92; $P=0.02$). Safety data reported an increase in mean serum creatinine level within 6 months of fenofibrate plus statin therapy use, followed by a gradual decline (mean change from baseline, 2.4%). However, change over time was not significantly different compared with statin monotherapy. Also, the proportions of participants with liver enzyme levels more than twice the upper limit of normal were similar between the two groups [62].

Furthermore, the ECLIPSE-REAL 2 study conducted in subjects with metabolic syndrome compared fenofibrate plus statin with omega-3 FA plus statin combination therapy based on 1:1 PS matching, and the results would be soon published. The primary endpoint of the study was 3-point major adverse CV events, comprising ischemic heart disease, ischemic stroke, and CV death. Incidence of all-cause mortality, hospitalization for HF, and adverse events of interest such as atrial fibrillation, hemorrhagic stroke, doubling of serum creatinine levels, and end-stage kidney disease were also evaluated.

GUIDELINES ON THE MANAGEMENT OF DYSLIPIDEMIA IN THE ASIAN REGION

A number of Asian countries have developed, or are in the process of developing clinical practice guidelines to improve the management of dyslipidemia with fibrate use:

(1) In individuals with a TG ≥ 500 mg/dL, immediate initiation of fibrates has been recommended to prevent acute pancreatitis [16,17].

(2) If TG levels persist at >200 mg/dL even after achieving the LDL-C target goal through therapeutic lifestyle modification and statin treatment, therapy with fibrate and omega-3 FAs can be considered [65].

(3) Statin plus gemfibrozil combination is not recommended over statin and fenofibrate combination therapy [17,18,66] due to the highest risk of myopathy with gemfibrozil among fibrates [18].

The recent Consensus recommendations by the Asian Pacific Society of Cardiology on dyslipidemia address the need for a unified management approach and are intended to guide clinicians and facilitate screening, early diagnosis, and treatment in this region [67].

However, dyslipidemia management should be patient-specific, considering the distinct baseline risk, clinical characteristics, comorbidities, as well as the individual concerns and preferences [67]. Clinicians should be aware of the factors that may restrict the uniform applicability of these consensus recommendations across all countries of the Asia Pacific region. The limiting factors may include accessibility and affordability of certain drugs, interventions, and other expertise, disparities in healthcare resources between countries; and currently recognized standards of care along with cultural aspects in respective countries [67].

CONCLUSIONS

Overall data suggest that fenofibrate treatment is effective and well-tolerated among Asian patients with dyslipidemia or hypertriglyceridemia and associated comorbidities. Recent evidence supports the potential role of fenofibrate in residual CV risk management, especially in patients with hypertriglyceridemia and/or low HDL-C level, despite appropriate statin therapy. However, the combination therapy with statins has potential risk of hepatic or renal side effects in vulnerable individuals that necessitate careful monitoring. Also, fenofibrate protects against prediabetes and diabetes-related CV complications by improving insulin sensitivity and β-cell function and has beneficial effects on microvascular complications (retinopathy and nephropathy). Furthermore, well-designed RCTs and real-world studies in Asian subjects are needed to confirm the benefit of fenofibrate focusing on metabolic syndrome or atherogenic dyslipidemia.

SUPPLEMENTARY MATERIALS

Supplementary materials related to this article can be found online at https://doi.org/10.4093/dmj.2023.0168.

CONFLICTS OF INTEREST

ORCID

Chaicharn Deerochanawong *https://orcid.org/0000-0001-9666-7050*
Sin Gon Kim *https://orcid.org/0000-0002-7430-3675*

FUNDING

ACKNOWLEDGMENTS

REFERENCES

1. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol 2021; 18:689-700.
2. Bazarbashi N, Miller M. Triglycerides: how to manage patients with elevated triglycerides and when to refer? Med Clin North Am 2022;106:299-312.
3. Wolska A, Yang ZH, Remaley AT. Hypertriglyceridemia: new approaches in management and treatment. Curr Opin Lipidol 2020;31:331-9.
4. Rygiel K. Hypertriglyceridemia: common causes, prevention and treatment strategies. Curr Cardiol Rev 2018;14:67-76.
5. Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol 2017;14:401-11.
6. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004;110:2678-86.
7. Lin CF, Chang YH, Chien SC, Lin YH, Yeh HY. Epidemiology of dyslipidemia in the Asia Pacific region. Int J Gerontol 2018; 12:2-6.
8. Mohamed-Yassin MS, Baharudin N, Daher AM, Abu Bakar N, Ramli AS, Abdul-Razak S, et al. High prevalence of dyslipidaemia subtypes and their associated personal and clinical attributes in Malaysian adults: the REDISCOVER study. BMC Cardiovasc Disord 2021;21:149.
9. Cho SM, Lee H, Lee HH, Baek J, Heo JE, Joo HJ, et al. Dyslipidemia fact sheets in Korea 2020: an analysis of nationwide population-based data. J Lipid Atheroscler 2021;10:202-9.
10. Ihm SH, Chung WB, Lee JM, Hwang BH, Yoo KD, Her SH, et al. Efficacy and tolerability of pitavastatin versus pitavastatin/fenofibrate in high-risk Korean patients with mixed dyslipidemia: a multicenter, randomized, double-blinded, parallel, therapeutic confirmatory clinical trial. Clin Ther 2020;42:2021-35.
11. Kim NH, Kim SG. Fibrates revisited: potential role in cardiovascular risk reduction. Diabetes Metab J 2020;44:213-21.
12. Sando KR, Knight M. Nonstatin therapies for management of dyslipidemia: a review. Clin Ther 2015;37:2153-79.
13. Lian X, Wang G, Zhou H, Zheng Z, Fu Y, Cai L. Anticancer properties of fenofibrate: a repurposing use. J Cancer 2018;9: 1527-37.
14. Moon JH, Kim K, Choi SH. Lipoprotein lipase: is it a magic target for the treatment of hypertriglyceridemia. Endocrinol Metab (Seoul) 2022;37:575-86.
15. Jiang S, Uddin MJ, Yu X, Piao L, Dorotea D, Oh GT, et al. Peroxisomal fitness: a potential protective mechanism of fenofibrate against high fat diet-induced non-alcoholic fatty liver disease in mice. Diabetes Metab J 2022;46:829-42.
16. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia in Korea. J Lipid Atheroscler 2019;8:78-131.
17. Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, et al. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc 2017;116:217-48.
18. Ministry of Health Malaysia. 5th Edition of clinical practice guidelines: management of dyslipidaemia 2017. Available from: https://www.moh.gov.my/moh/resources/Penerbitan/CPG/CARDIOVASCULAR/4.pdf (cited 2023 Sep 4).
19. Wang G, He L, Liu J, Yu J, Feng X, Li F, et al. Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. Cardiovasc Ther 2013;31:161-7.
20. Min YJ, Choi YH, Hyeon CW, Cho JH, Kim KJ, Kwon JE, et al. Fenofibrate reduces C-reactive protein levels in hypertriglycer-

idemic patients with high risks for cardiovascular diseases. Korean Circ J 2012;42:741-6.

21. Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, et al. Meta-analysis of safety of the coadminstration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol 2012; 110:1296-301.

22. Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. Clin Exp Pharmacol Physiol 2013;40:219-26.

23. Lee SH, Cho KI, Kim JY, Ahn YK, Rha SW, Kim YJ, et al. Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia. Atherosclerosis 2012;221:169-75.

24. Zhao S, Wang F, Dai Y, Lin L, Tong Q, Liao Y, et al. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. Int J Cardiol 2016; 221:832-6.

25. Park MS, Youn JC, Kim EJ, Han KH, Lee SH, Kim SH, et al. Efficacy and safety of fenofibrate-statin combination therapy in patients with inadequately controlled triglyceride levels despite previous statin monotherapy: a multicenter, randomized, double-blind, phase IV study. Clin Ther 2021;43:1735-47.

26. Woo Y, Shin JS, Shim CY, Kim JS, Kim BK, Park S, et al. Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: real-world results and factors associated with triglyceride reduction. PLoS One 2018; 13:e0205006.

27. Koh KK, Quon MJ, Shin KC, Lim S, Lee Y, Sakuma I, et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis 2012;220: 537-44.

28. Koh KK, Oh PC, Sakuma I, Lee Y, Han SH, Shin EK. Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. Int J Cardiol 2016;221:342-6.

29. Oikawa S, Yamashita S, Nakaya N, Sasaki J, Kono S. Effect of fenofibrate and ezetimibe combination treatment on lipid (EFECTL) study investigators. Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL Study. J Atheroscler Thromb 2017;24:77-94.

30. Wang HY, Jiao QP, Chen SY, Sheng J, Jiang H, Lu J, et al. Efficacy and safety of policosanol plus fenofibrate combination therapy in elderly patients with mixed dyslipidemia: a randomized,

controlled clinical study. Am J Med Sci 2018;356:254-61.

31. Parhofer KG, Laufs U. The diagnosis and treatment of hypertriglyceridemia. Dtsch Arztebl Int 2019;116:825-32.

32. Bao W, Kong R, Wang N, Han W, Lu J. PPAR-alpha agonist fenofibrate combined with octreotide acetate in the treatment of acute hyperlipidemia pancreatitis. PPAR Res 2021;2021: 6629455.

33. Liu J, Lu R, Wang Y, Hu Y, Jia Y, Yang N, et al. PPARα agonist fenofibrate reduced the secreting load of β-cells in hypertriglyceridemia patients with normal glucose tolerance. PPAR Res 2016; 2016:6232036.

34. Ma M, Liu H, Yu J, He S, Li P, Ma C, et al. Triglyceride is independently correlated with insulin resistance and islet beta cell function: a study in population with different glucose and lipid metabolism states. Lipids Health Dis 2020;19:121.

35. Lee CY, Huang KH, Lin CC, Tsai TH, Shih HC. A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates. ScientificWorldJournal 2012;2012:392734.

36. Feng X, Gao X, Jia Y, Xu Y. PPAR-α agonist fenofibrate reduces insulin resistance in impaired glucose tolerance patients with hypertriglyceridemia: a cross-sectional study. Diabetes Ther 2017;8:433-44.

37. Yan F, Tian L, Xiao Z, Li S, Fu M, Tian H. Comparison of the efficacy of fenofibrate and acipimox on plasma lipoprotein subclasses distribution in the Chinese population with type 2 diabetes mellitus and hypertriglyceridemia. Clin Lipidol 2014; 9:171-7.

38. Shinnakasu A, Yamamoto K, Kurano M, Arimura H, Arimura A, Kikuti A, et al. The combination therapy of fenofibrate and ezetimibe improved lipid profile and vascular function compared with statins in patients with type 2 diabetes. J Atheroscler Thromb 2017;24:735-48.

39. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.

40. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362: 1563-74.

41. Jo SH, Nam H, Lee J, Park S, Lee J, Kyoung DS. Fenofibrate use is associated with lower mortality and fewer cardiovascular events in patients with diabetes: results of 10,114 patients from the Korean National Health Insurance Service Cohort. Diabe-

tes Care 2021;44:1868-76.

42. Ferreira JP, Vasques-Novoa F, Ferrao D, Saraiva F, Falcao-Pires I, Neves JS, et al. Fenofibrate and heart failure outcomes in patients with type 2 diabetes: analysis from ACCORD. Diabetes Care 2022;45:1584-91.

43. Feng X, Gao X, Jia Y, Zhang H, Pan Q, Yao Z, et al. PPAR-α agonist fenofibrate decreased serum irisin levels in type 2 diabetes patients with hypertriglyceridemia. PPAR Res 2015;2015: 924131.

44. Ho MY, Wang CY. Role of irisin in myocardial infarction, heart failure, and cardiac hypertrophy. Cells 2021;10:2103.

45. Feng X, Gao X, Jia Y, Zhang H, Xu Y, Wang G. PPAR-α agonist fenofibrate decreased RANTES levels in type 2 diabetes patients with hypertriglyceridemia. Med Sci Monit 2016;22:743-51.

46. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022;387:1923-34.

47. d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, et al. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2014;57:2296-303.

48. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97.

49. Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the action to control cardiovascular risk in diabetes (ACCORD) eye study. Ophthalmology 2014;121:2443-51.

50. Ju HB, Zhang FX, Wang S, Song J, Cui T, Li LF, et al. Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients. Medicine (Baltimore) 2017;96:e7671.

51. Kawasaki R, Konta T, Nishida K. Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: a real-world observational analysis of a health claims database. Diabetes Obes Metab 2018;20:2351-60.

52. Kawasaki R, Kitano S, Sato Y, Yamashita H, Nishimura R, Tajima N, et al. Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan diabetes complication and its prevention prospective study (JDCP study 4). Diabetol Int 2018;10:3-11.

53. Kang EY, Chen TH, Garg SJ, Sun CC, Kang JH, Wu WC, et al.

Association of statin therapy with prevention of vision-threatening diabetic retinopathy. JAMA Ophthalmol 2019;137:363-71.

54. Shi R, Zhao L, Qi Y. The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study. BMC Ophthalmol 2018;18:100.

55. Lin YC, Chen YC, Horng JT, Chen JM. Association of fenofibrate and diabetic retinopathy in type 2 diabetic patients: a population-based retrospective cohort study in Taiwan. Medicina (Kaunas) 2020;56:385.

56. Meer E, Bavinger JC, Yu Y, VanderBeek BL. Association of fenofibrate use and the risk of progression to vision-threatening diabetic retinopathy. JAMA Ophthalmol 2022;140:529-32.

57. Kim NH, Choi J, Kim YH, Lee H, Kim SG. Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: a propensity-matched cohort study. Diabetes Metab 2023;49:101428.

58. Lim AK. Diabetic nephropathy: complications and treatment. Int J Nephrol Renovasc Dis 2014;7:361-81.

59. Keech A, Drury P, Davis TM, Donoghoe M, Laakso M, Whiting M, et al. Abstract 983: protection against nephropathy with fenofibrate in type 2 diabetes mellitus: the FIELD study. Circulation 2009;120:S419-20.

60. Sun X, Liu J, Wang G. Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. Lipids Health Dis 2020;19:103.

61. Yen CL, Fan PC, Lin MS, Lee CC, Tu KH, Chen CY, et al. Fenofibrate delays the need for dialysis and reduces cardiovascular risk among patients with advanced CKD. J Clin Endocrinol Metab 2021;106:1594-605.

62. Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ 2019;366:l5125.

63. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8.

64. Hermans MP. Impact of fenofibrate on type 2 diabetes patients with features of the metabolic syndrome: subgroup analysis from FIELD. Curr Cardiol Rev 2010;6:112-8.

65. Yang YS, Kim HL, Kim SH, Moon MK. Lipid management in Korean people with type 2 diabetes mellitus: Korean diabetes association and Korean society of lipid and atherosclerosis

consensus statement. Diabetes Metab J 2023;47:1-9.

66. Ferraro RA, Leucker T, Martin SS, Banach M, Jones SR, Toth PP. Contemporary management of dyslipidemia. Drugs 2022; 82:559-76.

67. Koh N, Ference BA, Nicholls SJ, Navar AM, Chew DP, Kostner K, et al. Asian pacific society of cardiology consensus recommendations on dyslipidaemia. Eur Cardiol 2021;16:e54.

Supplementary Table 1. Main characteristics of the studies in patients with dyslipidemia or hypertriglyceridemia with or without a high risk of CV disease

Study	Study design	Patient population	Study drug (no. of patients)	Comparator or control (no. of patients)	Treatment duration (and/or safety follow-up)	Outcomes with fenofibrate alone/in combination
Min et al. (2012) [20]	Retrospective case-control	Hypertriglyceridemia with high risk for CV disease	Fenofibrate (200 mg) (n=140)	General measures (a low-calorie and a low-fat diet and aerobic exercise) (n=140)	2 months	CRP levels were decreased in patients with high CRP and/or low HDL-C levels and without severe overweight
Lee et al. (2012) [23]	Randomized, open-label, multi-center study	Mixed hyperlipidemia with CV risk factors	Fenofibrate (160 mg/day) plus rosuvastatin (10 mg/day) (n=90)	Rosuvastatin (10 mg/day) (n=90)	Diet and lifestyle changes, 6 weeks; Treatment, 24 weeks; Safety, 4 weeks	Incidences of muscle or liver enzyme elevation; AEs were comparable with rosuvastatin alone
Zhao et al. (2016) [24]	Prospective, multi-center, single-arm, open-label, phase 4 study	Dyslipidemia and high CV risk	Fenofibrate (200 mg daily) add-on to statin (n=506)	-	Treatment, 8 weeks; Safety: additional 30 days after the final dose of fenofibrate	Significant decrease in TG and increase in HDL-C; No cases of myositis or rhabdomyolysis
Park et al. (2021) [25]	Prospective, multi-center, randomized, double-blind, phase 4 study	Patients with dyslipidemia, with controlled LDL-C and elevated TG	Choline fenofibrate (178.8 mg/day) plus statin (n=64)	Atorvastatin (10 or 20 mg) or rosuvastatin (10 mg) plus placebo (n=63)	8 weeks	Significantly reduced TG and increased HDL-C levels with no additional SAEs; No clinical problems in the combination group due to increased serum creatinine levels (by ~0.14 mg/dL); No differences in the liver function tests and serum creatine kinase levels and no cases of yopathy or rhabdomyolysis
Ihm et al. (2020) [10]	Multi-center, randomized, double-blind, parallel-group, therapeutic-confirmatory clinical trial	Mixed dyslipidemia and high CV disease risk	Pitavastatin (2 mg) plus fenofibrate (160 mg) plus a pitavastatin-matched placebo (n=174)	Pitavastatin (2 mg) plus a pitavastatin/fenofibrate-matched placebo (n=173)	Treatment, 8 weeks; Extension study, 16 weeks	Greater reduction in non-HDL-C levels from baseline to week 8; More efficacious in reducing levels of inflammatory markers such as fibrinogen and hsCRP and had a significant effect on remnant C
Woo et al. (2018) [26]	Retrospective observational	Patients with ≥1 CV risk factors, LDL-C lower than the target levels (as defined by NCEP ATP III guidelines), and TG ≥150 mg/dL	Fenofibrate (135–160 mg) for the first time (n=1,113)	-	Median follow-up, 4 months	The percentage reduction of TG was more in women, patients without DM, non-smokers, those with pre-treatment TG ≥500 mg/dL or median, with atherogenic dyslipidemia, or without statin use

dmj

Supplementary Table 1. Continued.

Study	Study design	Patient population	Study drug (no. of patients)	Comparator or control (no. of patients)	Treatment duration (and/or safety follow-up)	Outcomes with fenofibrate alone/in combination
Koh et al. (2012) [27]	Randomized, single-blind, placebo-controlled, parallel study	Hypertriglyceridemia	Fenofibrate (160 mg/day) (n=48)	Omega-3 FA (2 mg/day) (n=50) or placebo (n=49)	2 months	Significantly decreased non-HDL-C and TG/HDL-C, and increased HDL-C and ApoAI compared with placebo and omega-3 FA; A significant decrease in fasting insulin and increased plasma adiponectin and insulin sensitivity than omega-3 FA
Koh et al. (2016) [28]	Randomized, single-blind, placebo-controlled, parallel study	Hypertriglyceridemia	Fenofibrate (160 mg/day) plus omega-3 FA (2 mg/day) (n=49)	Fenofibrate alone (160 mg/day) (n=49) or placebo (n=48)	2 months	TGs and TG/HDL-C ratio were significantly decreased with combination therapy; Similar clinical benefits of combination and fenofibrate alone were noted for ApoB, non-HDL-C, FMD, CRP, and fibrinogen
Oikawa et al. (2017) [29]	Three-arm parallel-group, open-label randomized trial (EFECTL study)	Combined hyperlipidemia	Fenofibrate (200 mg/day capsule or 160 mg/day tablet) plus ezetimibe (10 mg/day) (n=107)	Fenofibrate alone (200 mg/day capsule or 160 mg/day tablet) (n=52) or ezetimibe alone (10 mg/day) (n=51)	52 weeks	Significantly greater improvements in LDL-C and TG levels with combination therapy; Safety profile was similar between combination and fenofibrate monotherapy
Wang et al. (2018) [30]	Randomized, controlled, clinical trial	Elderly patients with mixed dyslipidemia (age ≥60 years)	Micronized fenofibrate (200 mg/day) (n=31) or micronized fenofibrate (200 mg/day) plus policosanol (20 mg/day) (n=33)	Policosanol (20 mg/day) (n=34)	Dietary baseline period: 2 weeks; Treatment: 24 weeks	Combination therapy showed significantly greater reductions in TC, non-HDL-C, and LDL-C compared with fenofibrate monotherapy; Arterial stiffness (brachial-ankle pulse wave velocity and QoL) was also significantly improved with good tolerability

CV, cardiovascular; CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; AE, adverse event; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; SAE, serious adverse event; hsCRP, high-sensitivity C-reactive protein; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; DM, diabetes mellitus; FA, fatty acid; ApoB, apolipoprotein B; FMD, flow-mediated dilation; QoL, quality of life.